Abstract

Purpose: To evaluate the efficacy of vitrectomy combined with intravitreal dexamethasone implant vs. vitrectomy without the implant in patients with epiretinal membrane (ERM) by conducting a systematic review and meta-analysis. Methods: Studies that compared ERM vitrectomy with and without intraoperative dexamethasone implant with a follow-up ≥3 months were included. The primary outcome was mean best corrected visual acuity (BCVA) change between eyes undergoing ERM vitrectomy combined with dexamethasone implant (DEX group) and eyes undergoing ERM vitrectomy alone (control group) at 3 months. Secondary outcomes included mean BCVA change at 6 months and mean optical coherence tomography central macular thickness (CMT) change at both 3-months and 6-months follow-up. Mean differences (MDs) with their 95% confidence interval (95%CI) were calculated. Meta-analyses were based either on random effect model or fixed effect model according to heterogeneity. Results: Four studies were included. At 3 months, ERM vitrectomy combined with dexamethasone implant yielded a greater visual gain compared to vitrectomy alone (MD = 9.7; 95%CI = 2.6–16.8; p = 0.01). However, significant heterogeneity was found. A sensitivity analysis excluding the only retrospective non-randomized study confirmed a greater visual gain in the DEX group (MD = 7.1; 95%CI = 2.7–11.6; p < 0.01), with no heterogeneity. At 6 months, a non-significant but borderline difference in visual gain was shown between in the two groups (MD = 5.1; 95%CI = −0.3–10.5; p = 0.06), with no heterogeneity. Three-month analysis of CMT revealed a greater reduction in the DEX group (MD = −80.2; 95%CI =−149.1–11.2; p = 0.02), but with significant heterogeneity. A sensitivity analysis excluding the only retrospective non-randomized study allowed to reduce heterogeneity, but no difference in 3-months CMT change was found between the two groups (MD = −50.0; 95%CI = −106.2–6.2; p = 0.08). At 6 months, no difference in CMT change was shown between the two groups (MD = −48.5; 95%CI = −120.5–23.5; p = 0.19), with significant heterogeneity. Conclusions: Intraoperative dexamethasone implant in eyes undergoing vitrectomy for ERM provided a better visual outcome at 3 months compared to ERM vitrectomy without the implant, with limited evidence of better anatomic outcome as well. Further studies are needed to ascertain whether dexamethasone implant would ensure a significant long-term visual benefit as a result of a faster reduction of macular thickening.

Highlights

  • Idiopathic epiretinal membrane (ERM) represents one of the most common vitreoretinal interface abnormalities affecting the macula, whose incidence increases with age (Meuer et al, 2015; Zapata et al, 2017)

  • A systematic search of studies that compared vitrectomy for ERM with and without intraoperative intravitreal dexamethasone implant was conducted on PubMed, Medline and embase databases, from their inception to November 12th, 2020

  • This systematic review and meta-analysis demonstrated that eyes undergoing ERM vitrectomy combined with intraoperative dexamethasone had a better visual outcome at 3-months follow-up compared with those undergoing ERM vitrectomy without dexamethasone implant

Read more

Summary

Introduction

Idiopathic epiretinal membrane (ERM) represents one of the most common vitreoretinal interface abnormalities affecting the macula, whose incidence increases with age (Meuer et al, 2015; Zapata et al, 2017). The interest toward this condition has peaked following the introduction of high resolution imaging, namely spectral domain-optical coherence tomography (sd-OCT), which improved ERM diagnosis and characterization. In 1997, The Blue Mountains Eye Study based ERM diagnosis on retinal photograph and reported a 11.6% prevalence of ERM in 70–79 years aged people (Mitchell et al, 1997). The goal of the surgery is ERM removal with long-term favorable outcomes (De Bustros et al, 1988)

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.